Q2 EPS Forecast for Axsome Therapeutics Raised by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Zacks Research raised their Q2 2026 earnings estimates for shares of Axsome Therapeutics in a research note issued on Monday, October 13th. Zacks Research analyst Team now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.39). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($1.41) EPS, Q1 2027 earnings at $0.60 EPS, Q2 2027 earnings at $0.90 EPS, Q3 2027 earnings at $0.93 EPS and FY2027 earnings at $3.34 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million during the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.

AXSM has been the subject of several other research reports. Royal Bank Of Canada boosted their price target on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Needham & Company LLC reissued a “buy” rating and issued a $150.00 price target on shares of Axsome Therapeutics in a report on Monday, August 4th. B. Riley began coverage on shares of Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target for the company. Wells Fargo & Company raised shares of Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics currently has an average rating of “Buy” and an average price target of $177.93.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $129.58 on Wednesday. The firm has a market cap of $6.47 billion, a PE ratio of -25.56 and a beta of 0.52. The firm has a fifty day moving average of $118.06 and a 200 day moving average of $110.09. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. Axsome Therapeutics has a one year low of $75.56 and a one year high of $139.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC boosted its position in shares of Axsome Therapeutics by 71.4% during the 3rd quarter. CWM LLC now owns 5,151 shares of the company’s stock valued at $626,000 after acquiring an additional 2,146 shares during the last quarter. DAVENPORT & Co LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter valued at about $227,000. Assenagon Asset Management S.A. boosted its position in shares of Axsome Therapeutics by 62.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company’s stock valued at $35,800,000 after acquiring an additional 113,811 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Axsome Therapeutics by 136.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,215 shares of the company’s stock valued at $336,000 after acquiring an additional 1,856 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Axsome Therapeutics by 1.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after acquiring an additional 107 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $118.84, for a total transaction of $1,518,062.16. Following the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at $859,094.36. The trade was a 63.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Mark L. Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $115.96, for a total transaction of $1,159,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 243,332 shares of company stock worth $28,824,746. Company insiders own 22.30% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.